Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
F-18 alpha-methyl tyrosine PET studies in patients with brain tumors
Autore:
Inoue, T; Shibasaki, T; Oriuchi, N; Aoyagi, K; Tomiyoshi, K; Amano, S; Mikuni, M; Ida, I; Aoki, J; Endo, K;
Indirizzi:
Gunma Univ, Sch Med, Dept Nucl Med, Gunma 3718511, Japan Gunma Univ Gunma Japan 3718511 Med, Dept Nucl Med, Gunma 3718511, Japan Gunma Univ, Sch Med, Dept Neurosurg, Gunma, Japan Gunma Univ Gunma Japan unma Univ, Sch Med, Dept Neurosurg, Gunma, Japan Gunma Univ, Sch Med, Dept Diagnost Rdiol & Neuropsychiat, Gunma, Japan Gunma Univ Gunma Japan ept Diagnost Rdiol & Neuropsychiat, Gunma, Japan
Titolo Testata:
JOURNAL OF NUCLEAR MEDICINE
fascicolo: 3, volume: 40, anno: 1999,
pagine: 399 - 405
SICI:
0161-5505(199903)40:3<399:FATPSI>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; PROTEIN-SYNTHESIS RATE; CEREBRAL GLIOMAS; SPECT; FLUORODEOXYGLUCOSE; FLUORINE-18-FLUORODEOXYGLUCOSE; L-<1-C-11>TYROSINE; METABOLISM;
Keywords:
alpha-methyl tyrosine; brain tumor; PET;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Inoue, T Gunma8511,, Sch Med, Dept Nucl Med, 3-39-22 Showa Machi Maebashi,Gunma 371 Gunma Univ 3-39-22 Showa Machi Maebashi Gunma Japan 3718511 371
Citazione:
T. Inoue et al., "F-18 alpha-methyl tyrosine PET studies in patients with brain tumors", J NUCL MED, 40(3), 1999, pp. 399-405

Abstract

We have developed F-18-labeled alpha-methyl tyrosine (FMT) for PET imaging. The aim of this study was to evaluate the clinical application potential of FMT for patients with brain tumors. Methods: Eleven healthy volunteers and 20 patients with brain tumors were injected with 185 MBq (5 mCi) FMT. In3 healthy volunteers, whole-body imaging and urinary and plasma analysis were conducted for the assessment of the biodistribution of FMT. The normal range of cortical standardized uptake value (SUV) as a reference for comparing tumor SUV of FMT was estimated by using PET data obtained at 30 min postinjection in 8 healthy volunteers. Dynamic PET scans were conducted for 100 min in 4 healthy volunteers and for 30 min in 15 patients with brain tumors. The 10-min static images in another 4 volunteers and all patients were obtained at 30 min postinjection. In 13 patients, FMT uptake in the brain tumor was compared with F-18-fluorodeoxyglucose (FDG). Tumor-to-normal cortex count (T/N) ratio and tumor-to-white matter count (T/W) ratio and SUVs ofbrain tumors were determined on FMT and FDG PET images. Results: Approximately 1480 MBq (40 mCi) FMT were produced in one radiosynthesis. Percentage injected dose (%ID) of FMT in the brain ranged from 2.8% to 4.9%, and approximately 50%ID of FMT was excreted in urine during 60 min postinjection, ofwhich 86.6% was unmetabolized FMT A faint physiological brain uptake with SUV of 1.61 +/- 0.32 (mean +/- SD, n = 8) was observed in healthy volunteers. Tumor SUV of FMT ranged from 1.2 to 8.2, with mean value of 2.83 +/- 1.57 (n = 23), which was significantly higher than that of the cortical area in healthy volunteers (P < 0.01). T/N and T/W ratios of FMT were significantly higher than those of FDG (2.53 +/- 1.31 versus 1.32 +/- 1.46, P < 0.001;3.99 +/- 2.10 versus 1.39 +/- 0.65, P < 0.0001. respectively). Conclusion:FMT like other radiolabeled amino acids, can provide high-contrast PET images of brain tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/21 alle ore 10:25:12